BioLine Rx Ltd (BLRX)

0.90
0.02 2.50
NASDAQ : Health Care
Prev Close 0.92
Open 0.90
Day Low/High 0.88 / 0.92
52 Wk Low/High 0.71 / 1.88
Volume 40.11K
Avg Volume 184.60K
Exchange NASDAQ
Shares Outstanding 56.42M
Market Cap 51.91M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer

- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations -

BioLineRx To Report Second Quarter Results On August 11, 2016

BioLineRx To Report Second Quarter Results On August 11, 2016

Management to hold conference call at 10:00 a.m. EDT

BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration

BioLineRx Announces In-licensing Of Liver Fibrosis Project Under Strategic Collaboration

Novel drug candidate modulates immune system to reduce liver fibrosis in non-alcoholic steatohepatitis

BioLineRx To Report First Quarter 2016 Results On May 17, 2016

BioLineRx To Report First Quarter 2016 Results On May 17, 2016

Management to hold a conference call at 10:00 a.m. EDT

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016

BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016

- Results identify specific targets in the apoptotic pathway -

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML

BioLineRx Reports Successful Top-Line Results In Phase 2 Trial For AML

Data identify a potential biomarker for future selection of BL-8040-responsive AML patients

BioLineRx To Report Annual 2015 Results On March 10, 2016

BioLineRx To Report Annual 2015 Results On March 10, 2016

Management to hold a conference call at 10:00 a.m. EST

BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment

BioLineRx Receives Confirmation Of Medical Device Classification In Europe For Celiac Treatment

BL-7010 receives designation as Class IIb medical device

BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer

BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer

BioLineRx management to hold conference call this morning at 10:00 am EST to further discuss this immunotherapy collaboration

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions...

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific...

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast...

BioLineRx To Present At The LD Micro Main Event

BioLineRx To Present At The LD Micro Main Event

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third...

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited...

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose...